Atorvastatin Calcium

Licensed by Pfizer Catalog No.S2077

For research use only.

Atorvastatin Calcium is an inhibitor of HMG-CoA reductase used as a cholesterol-lowering medication that blocks the production of cholesterol. Atorvastatin Calcium induces apoptosis and autophagy.

Atorvastatin Calcium  Chemical Structure

CAS No. 134523-03-8

Selleck's Atorvastatin Calcium has been cited by 9 Publications

1 Customer Review

Purity & Quality Control

Choose Selective HMG-CoA Reductase Inhibitors

Biological Activity

Description Atorvastatin Calcium is an inhibitor of HMG-CoA reductase used as a cholesterol-lowering medication that blocks the production of cholesterol. Atorvastatin Calcium induces apoptosis and autophagy.
Targets
HMG-CoA reductase [1]
(Cell-free assay)
In vitro

Atorvastatin inhibits pre-proET-1 mRNA expression in a concentration- and time-dependent fashion (60-70% maximum inhibition) and reduces immunoreactive ET-1 levels (25-50%), this inhibitory effect is maintained in the presence of oxidized LDL (1-50 mg/mL). [1] Atorvastatin significantly reduces angiotensin II-induced and epidermal growth factor-induced ROS production in VSMCs. Atorvastatin downregulates mRNA expression of the NAD(P)H oxidase subunit nox1 in VSMCs, whereas p22phox mRNA expression is not significantly altered. Atorvastatin inhibits membrane translocation of rac1 GTPase, which is required for the activation of NAD(P)H oxidase. [2] Atorvastatin (0.1 μM) significantly diminishes NF-κB activation induced by Ang II and TNF-α in mononuclear cells and VSMC. Atorvastatin (1 μM) diminishes MCP-1 expression induced by Ang II, TNF-α and is reversed by Mevalonate only in Ang II-stimulated cells. Atorvastatin (1 μM) diminishes IP-10 expression induced by Ang II and by TNF-α in VSMC, and this reduction is partially reversed by Mevalonate. [3] Atorvastatin and Gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CHO NVzZPGY2TnWwY4Tpc44h[XO|YYm= M2n5XGtqKH[jbIXld{Bnd3Jic3;kbZVuKG[udX;y[ZNk\WmwIDixNEB2VSlidYD0ZYtmKGmwIF;BWHAySjFvdILhcpNn\WO2ZXSgR2hQKGOnbHzzMEBMcT1yLkS1{txONg>? M1fFWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NUexOFE2Lz5{M{W3NVQyPTxxYU6=
CHO NUn5dphRTnWwY4Tpc44h[XO|YYm= MYrwTWM2OCC4YXz1[ZMh\m:{IIPv[Il2dSCobIXvdoV{[2WrbjCoNVAhfU1rIIXweIFs\SCrbjDPRXRROUJzLYTyZY5{\mWldHXkJGNJVyClZXzsd{whUUN3ME2wMlgyOjh|zszNMi=> NXXETYlPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1O|E1OTVpPkKzOVcyPDF3PD;hQi=>
Me300 MXPDfZRwfG:6aXPpeJkh[XO|YYm= MojWO|IhcHK| MU\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDN[VMxOCClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUGuNu69VS5? NYDTd3V2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1N|M{OTZpPkKyOVM{OzF4PD;hQi=>
KB MlPWR5l1d3SxeHnjbZR6KGG|c3H5 NYjhRYdJPzJiaILz M1TzfGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtDKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MT65O:69VS5? MlLqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3M{OzNVYoRjJ{NUOzN|E3RC:jPh?=
CHO MnPuSpVv[3Srb36gZZN{[Xl? NYDzUopsU2lidnHseYV{KG[xcjDzc4RqfW1iZnz1c5Jme2OnaX6gLFExKHWPKTD1dJRic2ViaX6gU2FVWDGEMz30doFve2[nY4Tl[EBEUE9iY3XscJMtKEurPUKuOVjPxE1w Mnn1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3N{G0NVUoRjJ|NUexOFE2RC:jPh?=
CHO M{Phb2Z2dmO2aX;uJIF{e2G7 MkPSdGlEPTBidnHseYV{KG[xcjDzc4RqfW1iZnz1c5Jme2OnaX6gLFExKHWPKTD1dJRic2ViaX6gU2FVWDGEMz30doFve2[nY4Tl[EBEUE9iY3XscJMtKEmFNUC9N{4{QDh2NN88UU4> NFLEOWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W3NVQyPSd-MkO1O|E1OTV:L3G+
HeLa NH\wXIZEgXSxdH;4bYNqfHliYYPzZZk> NUDGSoxGPzJiaILz MnPIR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUSuNlLPxE1w M3f3[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUOzN|E3Lz5{MkWzN|MyPjxxYU6=
LN18 NXX5ZlBpS3m2b4TvfIlkcXS7IHHzd4F6 MUS3NkBpenN? NUDpPVF2S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVE5zODDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDDzeZJ3cX[jbDDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTZwOd88UU4> MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjV|M{OxOkc,OjJ3M{OzNVY9N2F-
LNZ308 MluwR5l1d3SxeHnjbZR6KGG|c3H5 MVW3NkBpenN? M1v0fWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGxPYjNyODDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVcvPDUQvF2u NG\XVmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkWzN|MyPid-MkK1N|M{OTZ:L3G+
LN229 MlPnR5l1d3SxeHnjbZR6KGG|c3H5 MVq3NkBpenN? MnqwR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUG4zOjliY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxic4Xyeol3[WxiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF05NjIQvF2u MmPtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3M{OzNVYoRjJ{NUOzN|E3RC:jPh?=
Caco2 NFLjWotEgXSxdH;4bYNqfHliYYPzZZk> MUC3NkBpenN? NVmyeZlpS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS2Glb{KgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0yQC55zszNMi=> Ml7BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3M{OzNVYoRjJ{NUOzN|E3RC:jPh?=
HCEC M2O3fGN6fG:2b4jpZ4l1gSCjc4PhfS=> M4\WUVczKGi{cx?= NUPJPVJxS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOHQzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDDzeZJ3cX[jbDDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTJyLkROwG0v NXTGTlZ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1N|M{OTZpPkKyOVM{OzF4PD;hQi=>
LN18 NIDWSXhHfW6ldHnvckBie3OjeR?= M3ftXVEhfG9iMzD1US=> MnPjNlQhcHK| MXPJcohq[mm2aX;uJI9nKESQQTDzfY51cGW|aYOgbY4hcHWvYX6gUG4yQCClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJRzcXSrYYTl[EB1cHmvaXTpcoUhcW6lb4Lwc5JifGmxbjDheEAyKHSxIEOgeW0h[W[2ZYKgNlQhcHK|IHL5JIJmfGFiY3;1cpRqdmd? M2\xRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUOzN|E3Lz5{MkWzN|MyPjxxYU6=
LN229 NXXIUZhtTnWwY4Tpc44h[XO|YYm= NXznOms3OSC2bzCzJJVO NHn1S5QzPCCqcoO= MVHJcohq[mm2aX;uJI9nKESQQTDzfY51cGW|aYOgbY4hcHWvYX6gUG4zOjliY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB1emm2aXH0[YQhfGi7bXnkbY5mKGmwY3;ydI9z[XSrb36gZZQhOSC2bzCzJJVOKGGodHXyJFI1KGi{czDifUBj\XSjIHPveY51cW6p NF;kcIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkWzN|MyPid-MkK1N|M{OTZ:L3G+
DAOY NFe4TZlyUFSVIHHzd4F6 NXPzPWJQeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFTBU3kh[2WubIO= M1\ifFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2 NWfkdHhYeUiWUzDhd5NigQ>? NV;2W4lTeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPKMWdDVTJiY3XscJM> MorOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
A673 NFP4SVdyUFSVIHHzd4F6 M{\YUJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy| NFzlPGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
BT-37 MmDmdWhVWyCjc4PhfS=> NHLVWWdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStN|ch[2WubIO= NWW2dnNWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
U-2 OS MkDPdWhVWyCjc4PhfS=> NGXicpByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiVT2yJG9UKGOnbHzz M1v3elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Saos-2 M1nFSJFJXFNiYYPzZZk> MXrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy| MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-SH MWrxTHRUKGG|c3H5 NWLYdoJJeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uW0hiY3XscJM> NIXLcHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
BT-12 MV7xTHRUKGG|c3H5 Mm\ldWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUGyJINmdGy| M1;vWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50 MoXSdWhVWyCjc4PhfS=> NYfK[I5MeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF;IV{02OCClZXzsdy=> MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
MG 63 (6-TG R) MWXxTHRUKGG|c3H5 MmPhdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE2JIE[zJEg3NVSJIGKpJINmdGy| M{HyRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Assay
Methods Test Index PMID
Growth inhibition assay Cell viability 25874930
In vivo

Atorvastatin reduces vascular mRNA expression of p22phox and nox1 and increased aortic catalase expression in statin-treated rats. [2] Atorvastatin inhibits the increase of hsCRP serum levels in the cholesterol-fed rabbits. Atorvastatin inhibits the increase in osteopontin expression throughout the valve leaflet in the hypercholesterolemic aortic valves. [5]

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO 100 mg/mL
(86.55 mM)
Water Insoluble
Ethanol Insoluble

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
2% DMSO+35% PEG300+2% Tween 80+ddH2O
For best results, use promptly after mixing.

4mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 1155.34
Formula

2(C33H34FN2O5).Ca

CAS No. 134523-03-8
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)[O-])O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4.CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)[O-])O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4.[Ca+2]

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04915183 Not yet recruiting Drug: Atorvastatin|Other: Placebo Hearing Loss|Head and Neck Cancer National Institute on Deafness and Other Communication Disorders (NIDCD)|National Institutes of Health Clinical Center (CC) January 18 2022 Phase 3
NCT04388501 Completed Drug: Milvexian|Drug: Atorvastatin Healthy Janssen Pharmaceutica N.V. Belgium June 7 2021 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Atorvastatin Calcium | Atorvastatin Calcium supplier | purchase Atorvastatin Calcium | Atorvastatin Calcium cost | Atorvastatin Calcium manufacturer | order Atorvastatin Calcium | Atorvastatin Calcium distributor